Bank of New York Mellon’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14.7M | Buy |
393,688
+34,969
| +10% | +$1.3M | ﹤0.01% | 1818 |
|
|
2026
Q1 | $13M | Sell |
358,719
-46,291
| -11% | -$2.07M | ﹤0.01% | 1780 |
|
|
2025
Q4 | $18.9M | Buy |
405,010
+5,376
| +1% | +$239K | ﹤0.01% | 1573 |
|
|
2025
Q3 | $16.6M | Buy |
399,634
+53,706
| +16% | +$1.72M | ﹤0.01% | 1639 |
|
|
2025
Q2 | $9.95M | Buy |
345,928
+1,349
| +0.4% | +$41.7K | ﹤0.01% | 1908 |
|
|
2025
Q1 | $11.6M | Sell |
344,579
-186
| -0.1% | -$6.95K | ﹤0.01% | 1777 |
|
|
2024
Q4 | $17.6M | Buy |
344,765
+32,825
| +11% | +$1.84M | ﹤0.01% | 1642 |
|
|
2024
Q3 | $15.9M | Sell |
311,940
-74,510
| -19% | -$3.84M | ﹤0.01% | 1700 |
|
|
2024
Q2 | $17.3M | Buy |
386,450
+89,972
| +30% | +$4.15M | ﹤0.01% | 1663 |
|
|
2024
Q1 | $13.9M | Sell |
296,478
-33,101
| -10% | -$1.3M | ﹤0.01% | 1783 |
|
|
2023
Q4 | $11.7M | Sell |
329,579
-162,468
| -33% | -$4.98M | ﹤0.01% | 1897 |
|
|
2023
Q3 | $14.6M | Buy |
492,047
+28,629
| +6% | +$590K | ﹤0.01% | 1718 |
|
|
2023
Q2 | $8.35M | Buy |
463,418
+40,629
| +10% | +$810K | ﹤0.01% | 2035 |
|
|
2023
Q1 | $6.79M | Buy |
422,789
+71,030
| +20% | +$1.31M | ﹤0.01% | 2132 |
|
|
2022
Q4 | $6.44M | Buy |
351,759
+10,277
| +3% | +$181K | ﹤0.01% | 2187 |
|
|
2022
Q3 | $6.71M | Buy |
341,482
+10,237
| +3% | +$209K | ﹤0.01% | 2140 |
|
|
2022
Q2 | $6.18M | Buy |
331,245
+14,208
| +4% | +$284K | ﹤0.01% | 2207 |
|
|
2022
Q1 | $6.96M | Sell |
317,037
-5,469
| -2% | -$111K | ﹤0.01% | 2262 |
|
|
2021
Q4 | $9.16M | Buy |
322,506
+20,161
| +7% | +$497K | ﹤0.01% | 2147 |
|
|
2021
Q3 | $6.37M | Buy |
302,345
+10,190
| +3% | +$213K | ﹤0.01% | 2371 |
|
|
2021
Q2 | $5.51M | Buy |
292,155
+5,578
| +2% | +$98K | ﹤0.01% | 2439 |
|
|
2021
Q1 | $4.38M | Buy |
286,577
+13,940
| +5% | +$216K | ﹤0.01% | 2498 |
|
|
2020
Q4 | $3.85M | Buy |
272,637
+95,325
| +54% | +$1.33M | ﹤0.01% | 2486 |
|
|
2020
Q3 | $2.78M | Sell |
177,312
-8,311
| -4% | -$127K | ﹤0.01% | 2492 |
|
|
2020
Q2 | $3.25M | Buy |
185,623
+149,591
| +415% | +$2.55M | ﹤0.01% | 2428 |
|
|
2020
Q1 | $529K | Buy |
36,032
+185
| +0.5% | +$3.79K | ﹤0.01% | 3331 |
|
|
2019
Q4 | $899K | Buy |
35,847
+1,183
| +3% | +$22.5K | ﹤0.01% | 3301 |
|
|
2019
Q3 | $521K | Sell |
34,664
-3,922
| -10% | -$76.3K | ﹤0.01% | 3514 |
|
|
2019
Q2 | $964K | Buy |
38,586
+12,608
| +49% | +$312K | ﹤0.01% | 3235 |
|
|
2019
Q1 | $591K | Buy |
25,978
+2,798
| +12% | +$68.8K | ﹤0.01% | 3472 |
|
|
2018
Q4 | $695K | Buy |
23,180
+7,367
| +47% | +$207K | ﹤0.01% | 3307 |
|
|
2018
Q3 | $453K | Buy |
+15,813
| New | +$469K | ﹤0.01% | 3690 |
|
Other funds holding CRNX
FCM
DCM
JT
Bank of New York Mellon's CRNX Position: Q2 2026 in Review
Bank of New York Mellon increased its Crinetics Pharmaceuticals (CRNX) stake by 9.7% in Q2 2026, buying an estimated $1.3M and bringing the position to 393,688 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1818.
Bank of New York Mellon first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. The position peaked at $18.9M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- Bank of New York Mellon held 393,688 shares of Crinetics Pharmaceuticals worth $14.7M as of Q2 2026.
- Bank of New York Mellon bought 34,969 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.3M.
- Crinetics Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1818 holding.
- Bank of New York Mellon first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- Bank of New York Mellon's Crinetics Pharmaceuticals position peaked at $18.9M in Q4 2025.
- 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.